Related Experiment Video
Updated: Aug 19, 2026
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
[Malignant germ cell tumours. Multicenter prospective trial in Polish Pediatric Group for Solid Tumours (years
Stefan Popadiuk1, Maria Korzon, Małgorzata Szumera
1Klinika Pediatrii, Gastroenterologii i Onkologii Dzieciecej Akademii Medycznej w Gdańsku.
Insights
Treatment outcomes for pediatric malignant germ cell tumors in Poland are favorable. This multicenter trial shows high survival rates comparable to international standards, indicating effective therapeutic strategies.
Area of Science:
- Pediatric Oncology
- Malignant Germ Cell Tumors
- Clinical Trials
Background:
- Germ cell tumors represent approximately 3% of all pediatric cancers.
- A multicenter trial in Poland, initiated in 1998, focused on treating these rare malignancies.
Purpose of the Study:
- To evaluate the outcomes of treating pediatric malignant germ cell tumors in Poland.
- To compare treatment results with international data.
Main Methods:
- 95 children (1 month to 17 years) with germ cell tumors were registered.
- Diagnosis was histopathological in 88% and imaging/biochemical in 12%.
- Treatment followed the French TGM'95 protocol, categorizing patients into standard and high-risk groups.
Main Results:
- 91% of patients who completed therapy achieved complete remission.
- Survival rates were 89% for high-risk and 93% for standard-risk groups.
- Median follow-up was 31 months; 7 deaths occurred, all due to progressive disease.
Conclusions:
- The treatment outcomes for malignant germ cell tumors in Poland are favorable.
- Results are comparable to those reported by other international study groups.
Unlabelled:
Germ cell tumors constitute about 3% of all pediatric malignancies. Since 1998 the multicenter trial was initiated in Poland.
Material And Methods:
95 children (aged from 1 month to 17 years--mean 9.2 years) were registered. There were 38 boys and 57 girls. Diagnosis was made on histopathological examination in 88% patients (pts) and in 12% was established on imaging and biochemical findings (elevated AFP). Mixed germ cell tumor and yolk sac tumor prevelaged. AFP was elevated in 72% pts; in 26% it was over 15.000. Primary tumor was localized in gonads (59%) and in sacrococcygeal region (30%). Following disease stages were identified: I and II--41% pts, III--34%, IV--25%. All patients were treated according to French TGM'95 protocol. 43 belonged to high risk and 52 to standard risk group. 77 children completed therapy, 15 continue treatment and 3 were lost from follow-up.
Results:
Among children who were off therapy, 70 (91%) are alive in a complete remission (second remission in 3 cases). Survival in high risk group is 89%, while in standard risk group is 93%. Median time of follow-up is 31 months from the beginning of treatment and 25 months after completion of therapy. 7 children died; all had progressive disease.
Conclusion:
The outcome of malignant germ cell tumors treatment in Poland is favourable and comparable to results showed by other study groups in the world.
